Pacer Advisors Inc. Acquires 4,118 Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Pacer Advisors Inc. raised its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 12.7% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,552 shares of the biopharmaceutical company’s stock after acquiring an additional 4,118 shares during the quarter. Pacer Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $4,788,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. FMR LLC raised its position in shares of Alexion Pharmaceuticals by 10.4% during the 1st quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock worth $3,939,729,000 after purchasing an additional 2,746,055 shares during the last quarter. Jennison Associates LLC lifted its holdings in Alexion Pharmaceuticals by 17.3% in the 1st quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after buying an additional 1,512,545 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in Alexion Pharmaceuticals by 12.9% in the 1st quarter. Clearbridge Investments LLC now owns 5,810,033 shares of the biopharmaceutical company’s stock worth $785,400,000 after buying an additional 665,574 shares in the last quarter. Artisan Partners Limited Partnership lifted its holdings in Alexion Pharmaceuticals by 220.9% in the 1st quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after buying an additional 2,924,550 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Alexion Pharmaceuticals by 2.0% in the 1st quarter. Northern Trust Corp now owns 2,961,031 shares of the biopharmaceutical company’s stock worth $400,272,000 after buying an additional 58,998 shares in the last quarter. 92.67% of the stock is currently owned by institutional investors.

NASDAQ ALXN traded up $2.57 on Friday, hitting $102.85. 106,028 shares of the stock were exchanged, compared to its average volume of 2,889,419. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.04 and a quick ratio of 3.56. The business’s fifty day moving average is $112.03 and its 200 day moving average is $125.31. Alexion Pharmaceuticals, Inc. has a 52 week low of $92.56 and a 52 week high of $141.86. The company has a market capitalization of $21.87 billion, a PE ratio of 14.53, a P/E/G ratio of 0.93 and a beta of 1.67.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.13 by $0.51. The firm had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.18 billion. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The business’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same period in the prior year, the company posted $2.07 earnings per share. Analysts predict that Alexion Pharmaceuticals, Inc. will post 9.02 EPS for the current fiscal year.

In other news, insider Aradhana Sarin sold 578 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $132.00, for a total transaction of $76,296.00. Following the completion of the sale, the insider now owns 30,201 shares of the company’s stock, valued at approximately $3,986,532. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Indrani Lall Franchini sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $132.78, for a total transaction of $597,510.00. Following the sale, the executive vice president now directly owns 29,627 shares of the company’s stock, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. 4.08% of the stock is owned by company insiders.

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Friday, August 30th. Wedbush began coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, May 22nd. They issued an “outperform” rating and a $173.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, July 31st. They set an “overweight” rating and a $172.00 target price for the company. Credit Suisse Group reduced their target price on shares of Alexion Pharmaceuticals from $154.00 to $146.00 and set an “outperform” rating for the company in a report on Friday. Finally, ValuEngine downgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $162.53.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Recommended Story: What is a CD ladder?

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.